20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T78956 | PROTAC BRD3/BRD4-L degrader-2 | Epigenetic Reader Domain | |
PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits robust antitumor activity in mouse xenograft models, serving... | |||
T8932 | GSK046 | iBET-BD2 | Epigenetic Reader Domain |
GSK046 (iBET-BD2) is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins(IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively). It has immunom... | |||
T2120 | I-BET151 | GSK1210151A | Epigenetic Reader Domain |
I-BET151 (GSK1210151A) (GSK1210151A) is a specific BET inhibitor for BRD2/3/4 (IC50: 0.5/0.25/0.79 μM, in cell-free assays). | |||
T23820 | BRD32048 | BRD-32048,BRD 32048 | DNA/RNA Synthesis |
BRD32048 is the ETV1 transcription factor oncoprotein inhibitor. | |||
T8233 | BRD3308 | Apoptosis , HIV Protease , HDAC | |
BRD3308 is a highly selective inhibitor of HDAC3(IC50 of 54 nM), attenuating PE-mediated phosphorylation of ERK but not JNK. | |||
T30578 | BRD3067 | BRD-3067,BRD 3067 | |
BRD3067 is a negative control for tubastatin A. | |||
T61578 | BRD3731 | ||
BRD3731 is a selective inhibitor of GSK3β, demonstrating an IC50 value of 15 nM for GSK3β and 215 nM for GSK3α. Due to its inhibitory properties, BRD3731 holds promise for investigating various medical conditions, includ... | |||
T39457 | (R)-BRD3731 | (R)-BRD3731 | |
(R)-BRD3731, a GSK3 inhibitor, specifically compound example 273. It exhibits inhibitory activity with respective IC50 values of 1.05 μM for GSK3β and 6.7 μM for GSK3α. | |||
T5435 | ARV-771 | Epigenetic Reader Domain | |
ARV-771 is a potent BET degrader based on PROTAC technology with Kds of 34, 4.7, 8.3, 7.6, 9.6, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively[1]. | |||
T22345 | INCB054329 | INCB-054329,INCB-54329,INCB-54329 | Epigenetic Reader Domain |
INCB054329, a structurally distinct bromodomain and extraterminal domain (BET) inhibitor, inhibits BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2 with IC50 values of 44 nM, 5 nM, 9 nM, ... | |||
T19935 | XD14 | Epigenetic Reader Domain | |
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively). | |||
T10638 | BY27 | Epigenetic Reader Domain | |
BY27 is a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4 and BRDT, and suppresses tumor growth. | |||
T6021 | GSK1324726A | I-BET726 | Apoptosis , Epigenetic Reader Domain |
GSK1324726A (I-BET726) is a greatly specific inhibitor of BET family proteins for BRD2(IC50=41 nM), BRD3(IC50=31 nM), and BRD4 (IC50=22 nM). | |||
T9703 | GSK778 | Epigenetic Reader Domain | |
GSK778 is a potent and selective inhibitor of BD1 bromodomain such as BRD2 BD1 (IC50s = 75 nM), BRD3 BD1 (IC50s = 41 nM), BRD4 BD1 (IC50s = 41 nM), and BRDT BD1 (IC50s = 143 nM). GSK778 inhibits proliferation, induces a ... | |||
T12112 | MS402 | Epigenetic Reader Domain | |
MS402 is a novel BD1-selective BET BrD inhibitor. | |||
TQ0253 | PLX51107 | Epigenetic Reader Domain | |
PLX51107 is a potent and selective BET inhibitor (Kds: 1.6, 2.1, 1.7, and 5 nM for BRD2-BD1, BRD3-BD1, BRD4-BD1, and BRDT-BD1). | |||
T9703L | GSK778 hydrochloride | Epigenetic Reader Domain | |
GSK778 hydrochloride hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 ... | |||
T10773 | CF53 | Epigenetic Reader Domain , CDK | |
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT B... | |||
T28628 | RVX-297 | RVX297 | Epigenetic Reader Domain |
RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein. | |||
T15484 | HJB97 | Epigenetic Reader Domain | |
HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2... |